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The hallmark of primary cutaneous CD30þ large Tcell
lymphoma are large lymphoid tumor cells, at least 75%
of which, by de¢nition, must be positive for CD30. The
relatively benign clinical course of this lymphoma type
has been explained with CD30-induced apoptosis,
on the assumption that expression of CD30 de¢nes the
tumor clone; however, this hypothesis has not been
tested on the molecular level to date. In this study we
analyzed CD30þ cells in four patients with primary cu-
taneous CD30þ large T cell lymphoma by single cell
polymerase chain reaction of Tcell receptor-c genes fol-
lowed by sequencing. Here, we demonstrate that most
of the large CD30þ atypical cells possessed identical
T cell receptor-c gene rearrangements, indicative of
clonal proliferation. Nevertheless, polyclonally rear-
ranged T cells were present in all CD30þ samples stu-
died. In addition, one patient showed a second clone in
a separate biopsy and three of four patients showed
chromosomal imbalances as revealed by comparative
genomic hybridization. Taken together, our data sug-
gest that the CD30þ population in primary cutaneous
CD30þ large T cell lymphoma indeed contains the
tumor clone, thus providing molecular support for a
link between clinical course and CD30-related signal-
ing. Importantly, however, CD30 expression does not
de¢ne the tumor clone as bystander T cells, as well as
occasional additional clones, are also present in this
population. Key words: CD30þ /lymphoma/CTCL/Single
cell analysis/clonality. J Invest Dermatol 120:670 ^675, 2003
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D30 expression represents a diagnostic parameter in
several lymphoproliferative disorders. A cytokine
receptor of the tumor necrosis factor receptor super-
family, CD30 is mainly restricted to the large cell
variants of non-Hodgkin lymphoma, including the
primary cutaneous T cell lymphomas (pCTCL), as well as Reed^
Sternberg cells in Hodgkin’s disease (Schwab et al, 1982; Stein et al,
1985; Smith et al, 1993;Willemze and Beljaards, 1993; Falini et al,
1995; Gruss et al, 1996; Willemze et al, 1997; Bekkenk et al, 2000;
Willemze and Meijer, 2000). Predominant CD30 expression indi-
cates a favorable prognosis in pCTCL (Willemze and Beljaards,
1993, Willemze et al, 1997; Bekkenk et al, 2000), in contrast
to Hodgkin’s disease and nodal CD30þ anaplastic large cell
lymphoma (Tilly et al, 1997; Falini et al, 1999).
Primary cutaneous CD30þ large T cell lymphomas (CD30þ
large pCTCL) form a distinct entity within the European Organ-
ization for Research andTreatment of Cancer classi¢cation of pri-
mary cutaneous lymphomas. Although histologically pCTCL is
subdivided into anaplastic (80%) and pleomorphic or immuno-
blastic (20%) subtypes, all types show an identical clinical
presentation with nodules and tumors (Willemze and Beljaards,
1993; Willemze et al, 1997; Bekkenk et al, 2000). Lymphoma
cells show a nodular distribution within the dermis and subcutis
but not the epidermis, typically featuring round, oval, or
irregularly shaped nuclei, prominent nucleoli, and abundant
cytoplasm. The large CD30þ cells are CD4þ with varying
loss of pan-T cell antigens (CD2, CD3, CD5). By de¢nition
CD30 is expressed on more than 75% of morphologically
atypical cells. Because of these features and clonal T cell
receptor (TCR)-g rearrangement present in bulk lymphoma
DNA it is generally assumed that the large atypical CD30þ
cells represent the tumor cell population (Willemze and
Beljaards, 1993; Willemze et al, 1997; Bekkenk et al, 2000). To
date, however, there exist no molecular data supporting this
assumption. Therefore, we investigated TCR-g rearrangements
of single cells found within the CD30þ cell population of
pCTCL.
MATERIALS ANDMETHODS
Patient I A 36 y old male initially developed a single erythematous
nodule on the left lower leg. After ruling out systemic disease (using chest
X-ray and ultrasound of abdomen and lymph nodes as well as bone
marrow biopsy), CD30þ large pCTCL was diagnosed. Various treatment
modalities, including excision, radiotherapy, acitretin, interferon a, and
chemotherapy with methotrexate and CHOP (Cyclophosphamide,
Hydroxydaunomycin, Oncovin, and Prednisone) did not induce complete
remission (Fig 1IA). Three years after the occurrence of the ¢rst skin lesion
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the patient died of cerebral metastases and multiple skin involvement.
Biopsies from the initial lesion showed a CD30þ large pCTCL
in¢ltrating the entire dermis down to the subcutaneous fatty tissue.
Atypical cells appeared as medium- to large-sized cells with a CD3^,
CD4þ, CD30þ phenotype and a mitotic rate of about 70% (Fig
1IB,IC). Molecular biologic investigation of blood and skin samples
revealed a monoclonal TCR-g gene rearrangement via polymerase chain
reaction (PCR) from bulk DNA and following £uorescent fragment
analysis (FFA). For single cell PCR, CD30þ cells were dissected from the
dermal in¢ltrate as described below.
Patient II A 75 y old male with a CD30þ large pCTCL presented with
a single erythematous nodule on the left elbow without extracutaneous
involvement as documented by chest X-ray, ultrasound of the abdomen
and peripheral lymph nodes and computed tomography of the chest and
abdomen. Excision and postexcisional radiotherapy induced complete
remission of about 15 mo duration. Thereafter, new lesions developed on
the left hand and lower arm (Fig 1IIA), which were excised. Eight
months later this patient is alive in partial remission. Biopsy from the
initial lesion showed a CD30þ large pCTCL in¢ltrating the whole
dermis. Atypical cells were medium sized to large sized with a CD3^,
Figure1. Patients with CD30þ large primary cutaneous Tcell lymphoma. Patient I, lower leg; patient II, ¢nger; patient III, upper leg, biopsy IIIa;
patient IV, hand wrist. (A) Clinical occurrence. (B) Hematoxylin and eosin staining of lesional skin, original magni¢cation 40. (C) Immunohistochemical
anti-CD30-staining of lesional skin, original magni¢cation 40.
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CD4þ, CD30þ phenotype and a mitotic rate of almost 100% (Fig
1IIB,IIC). Monoclonal TCR-g rearrangements were detected in blood
samples as well as skin samples by PCR from bulk DNA followed by
FFA. For single cell PCR, CD30þ cells were dissected from the dermal
in¢ltrate as described below.
Patient III A 62 y old female with a CD30þ large pCTCL presented
with multiple erythematous papules on the left upper leg (Fig 1IIIA).
The patient was treated with so-called mimotope vaccination therapy
(two nonapeptides mimicking unknown tumor antigens) for a total of
10 mo (Linnemann et al, 2000, 2001). After 2 mo of treatment complete
remission was achieved. Relapse occurred after an additional 3 mo, and
the vaccination therapy was continued leading to a second complete
remission 3 mo later. A second, very aggressive relapse of skin lesions, as
well as tumor involvement of the bone marrow and lymph nodes,
occurred 10 mo after the beginning of therapy. For that reason,
vaccination therapy was discontinued. The patient was treated with
CHOP chemotherapy and died 19 mo after occurrence of the ¢rst skin
lesions.
Biopsy of the initial lesion showed an in¢ltrate extending through the
whole dermis up to the subcutaneous fatty tissue. Morphologically,T cells
were medium-sized cells with a CD3þ, CD4þ, CD30þ phenotype and a
mitotic rate of about 10%. AT cell population with a monoclonal TCR-g
rearrangement was detected in all blood and skin samples. A medium-sized
pleomorphic T cell lymphoma with CD30 expression was diagnosed.
Subsequent lesions showed large CD30þ tumor cells with aberrant
phenotypes. For single cell PCR, CD30þ cells were dissected from the
dermis of two separate skin biopsies and from one blood sample:
Skin biopsy IIIa This skin biopsy was taken from a papule developing dur-
ing the ¢rst relapse after mimotope vaccination. Its histologic and morpho-
logic features were identical to pretreatment biopsies (Fig 1IIIB,IIIC).
Skin biopsy IIIb A second nodule was excised after 10 mo of mimotope
vaccination, during an aggressive relapse and showed an in¢ltrate of the
whole dermis reaching the subcutaneous fatty tissue. Tcells were large cells
with a loss of CD3 and CD4 expression (CD3^, CD4^, CD30þ pheno-
type) and a mitotic rate of 90^100%. Analysis of blood skin samples by
PCR from bulk DNA followed by FFA revealed a T cell population with
a biallelic TCR-g rearrangement in theVg2 primer set. Disease progression
into a CD30þ anaplastic large T cell lymphoma was diagnosed.
Blood sample IIIc Because of leukemic manifestation of T cell lymphoma,
we also dissected single large CD30þ blood lymphocytes from a cytospin
slide to compare TCR-g genes of these cells with cells from skin biopsies
(IIIa,b). The leukemic cells exhibited the same phenotype as those de-
scribed in biopsy IIIb.
Patient IV A 24 y old male presented with plaques on the right lower
arm and wrist. By histology, the diagnostic criteria of CD30þ large
pCTCL were met (see below); there was no evidence of systemic disease
(by X-ray, ultrasound of abdomen and lymph nodes) (Fig 1IVA).
Treatment with local electron beam irradiation of the right lower arm
induced complete remission, lasting 3 mo at the time of writing.
Skin specimen, analyzed by single cell PCR, showed a subepidermal
CD30þ atypical T cells with a proliferation rate of 50% (Fig 1IVB,IVC).
Almost all CD30þ large atypical cells were CD3^ and CD4^.
Routine molecular biologic investigation (FFA^TCR-g) revealed clonal
TCR rearrangements in skin biopsy and a polyclonal PCR product in
blood.
All human studies were performed in accordance to the Declaration of
Helsinki Principles.
Preparation of single cells from lesional skin sections via
micromanipulation The skin biopsies were snap frozen in liquid
nitrogen and stored at ^801C. Frozen skin sections (10 mm thick) were
stained with monoclonal mouse anti-CD30 (DAKO, Glostrup, Denmark)
using biotinylated Fab anti-mouse followed by streptavidin-peroxi-
dase conjugated complexes (LSAB-Kit 2: DAKO, Hamburg, Germany)
and hydrogen peroxidase^chromogen (AEC Substrate System: DAKO,
Hamburg, Germany) as developing reagents. Subsequently, counterstain-
ing with hematoxylin was performed.
CD30þ cells were dissected microscopically (Nikon, Dˇsseldorf,
Germany) by means of a hydraulic micromanipulator (Narishige,
Dˇsseldorf, Germany). Thereafter, single cells were aspirated into a
micropipette (Narishige), placed into 20 ml PCR bu¡er supplemented
with 1ng rRNA per ml (both from Boehringer, Mannheim, Germany),
and stored at ^201C. Photographs were taken before and after micro-
manipulation of each cell.
Preparation of single cells from peripheral blood In the case of
patient III CD30þ blood cells were investigated in addition to the skin
samples. Peripheral blood mononuclear cells were prepared from 10 ml
heparinized blood (sample IIIc) by density gradient centrifugation using
Ficoll Hypaque (Pharmacia, Freiburg, Germany). Peripheral blood
mononuclear cells were cytospun on slides. Immunohistologic staining
and micromanipulation of single CD30-positive cells was subsequently
performed as 0described above.
PCR ampli¢cation of rearranged single cell TCR-c genes and
sequence analysis Initially, cells were incubated with 0.25 mg per ml
Proteinase K (Boehringer) for 50 min at 551C and for an additional
10 min at 951C (enzyme inactivation). Rearranged TCR-g genes were
ampli¢ed by a seminested PCR with primers Vg1 (50CTACATCC-
ACTGGTACCT 30), recognizing Vg1^Vg8 gene families (Volkenandt
et al, 1993), Vg9ext (ATTGGTATCGAGAGAGAC), Vg10/11ext
(CACTGGTACKKGCAGAAAC) (Muche et al, 1997), and Jg1/2
(50CAACAAGTGTTGTTCCAC 30) in the ¢rst round, and with Vgseq
(50AGRCCCCACAGCRTCTTC 30), recognizing Vg1^Vg8 gene families,
Vg9int (GGAAAGGAATCTGGCATTCCG), Vg10 (AATCCGCAG-
CTCGACGCAGCA), and Vg11 (GCTCAAGATTGCTCAGGTGGG)
(Trainor et al, 1991) in the second round.
The reaction mix (50 ml) for the ¢rst round of ampli¢cation consisted
of 1PCR bu¡er (Boehringer), 2.5 mM MgCl2 (Boehringer), 200 mM of
each nucleotide (deoxyadenosine triphosphate, deoxythymidine triphos-
phate, deoxycytidine triphosphate, deoxyguanosine triphosphate) (AGS,
Heidelberg, Germany), 7 nM of each primer, and 3.5 U Expand high
¢delity Taq-Polymerase (Boehringer). PCR ampli¢cation was carried out
on a Personal Cycler (Biometra, G˛ttingen, Germany): one cycle at 951C
for 2 min, 651C for 1 min (addition of Taq-Polymerase), and 721C for 1
min, followed by 35 cycles at 951C for 1 min, 581C for 1 min and 721C
for 1 min, and a ¢nal extension at 721C for 5 min. The second round of
PCRwas carried out using 1 ml of the PCR product from the ¢rst round.
Reaction mixture: 1PCR bu¡er (Boehringer), 2.5 mM MgCl2
(Boehringer), 200 ml of each nucleotide (deoxyadenosine triphosphate,
deoxythymidine triphosphate, deoxycytidine triphosphate, deoxy-
guanosine triphosphate) (AGS), 7 nM of each primer and 1 U Taq-
polymerase (Boehringer). The second round cycle program was carried
out on aTrio-Thermoblock (Biometra) and consisted of one cycle at 951C
for 2 min, 681C for 5min (addition of Taq-Polymerase), and at 721C for 1
min, 45 cycles at 951C for 1 min, at 581C for 1 min, 721C for 1 min, and a
¢nal extension at 721C for 5 min. A 5 ml aliquot of the reaction mixture
was analyzed on a 2% agarose gel for successful ampli¢cation.
In order to avoid contamination with DNA, micromanipulation, ¢rst
and second round of PCR were carried out separately in three di¡erent
rooms. Every 10 tubes one tube without cells was inserted as negative
control, failing to show any products. PCR products were puri¢ed using
the Gel DNA Extraction Kit (Boehringer) followed by direct sequencing
with 5 ml Dye Terminator Cycle Sequencing Ready Reaction Kit (Perkin
Elmer,Weiterstadt, Germany) on the automated DNA Sequencing System
ABI 373A (Perkin Elmer Applied Biosystems,Weiterstadt, Germany) using
30 ng puri¢ed PCR product and 5 mM Vgseq,Vg9,Vg10, and Vg11 primer.
Sequence evaluation was done using Sequence Navigators software
(Perkin Elmer Applied Biosystems). DNA sequences were analyzed online
using DNA BLOTs software (created by H.H. Althaus) and compared
with the EMBL gene bank data (Heidelberg, Germany) for known TCR-
g genes. In total, 257 single CD30þ cells were analyzed. Two hundred and
thirty were localized in the dermis or in the subcutaneous fatty tissue.
Twenty-seven CD30þ cells were isolated from a cytospin sample of
peripheral blood lymphocytes. DNA could be ampli¢ed and sequenced in
137 of 257 isolated single CD30þ cells, what represents a method relevant
e⁄cacy (Kˇppers et al, 1995).
FFA^TCR-c Primers Vg1 and Vg2 (V9, V10/11) or Jg1/2 were 50 -labeled
with 5-carboxy-£uorescein (FAM). Labeled PCR products or product
mixtures were subjected to FFA on the ABI 310 PRISM (capillary; PE
Applied Biosystems) or, as indicated, on the ABI 373A (polyacrylamide
gel electrophoresis) sequencers (PE Applied Biosystems). For FFA on the
ABI 310 PRISM, 12 ml deionized formamide and 0,5 ml Genescan 500TM
ROX internal lane standard (PE Applied Biosystems) were added to 1 ml of
the PCR ampli¢cation, denatured at 901C for 2 min and chilled on ice to
produce single stranded DNA. Each run was performed at 601C and 15 kV
with a 5 s injection and 36 min separation time in a 47 cm POP 6-¢lled
capillary (PE Applied Biosystems).
For analysis on the ABI 373A, 5 ml deionized formamide, 0.5 ml
ethylenediamine tetraacetic acid, 0.5 ml GeneScan 2500TM ROX internal
lane standard (PE Applied Biosystems) and 0.5 ml dextran blue were
added to 2 ml of the labeled PCR product, denatured as described above
and loaded on to a 4.75% polyacrylamide gel (LC 6 premixed gel, FMC
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Bioproducts, Rockland MD). The runs of both sequencers were analyzed
using the ‘‘GeneScan 372’’ software (PE Applied Biosystems).
Comparative genomic hybridization (CGH) Lesional skin samples
of all four patients were investigated for chromosomal aberrations
(Table I) as described byTonnies et al (2001).
RESULTS
Large, atypical CD30þ cells of four patients with CD30þ large
pCTCL were examined by single cell PCR analysis followed by
sequencing of the TCR-g chain genes (Table I). The majority of
dermal CD30þ cells displayed identical individual TCR-g genes
in all patients (patient I: 81.8%; patient II: 81.5%; patient III:
biopsy IIIb 74.0%, blood IIIc 78.6%; patient IV: 78.2%). The only
exception was skin sample IIIa of patient III containing only a
minority of cells with an identical TCR-g rearrangement (patient
III: biopsy IIIa 18.2%). For details seeTable I.
Two di¡erent clonal TCR-g chain genes could be ampli¢ed
from several cells of patients I^IV. Therefore, both TCR-g genes
can be assigned to a biallelic, clonal (malignant) Tcell population
(Table II); however, the remainder of CD30þ Tcells analyzed in
this investigation was polyclonal (sequences not shown). In 18 of
38 of these polyclonal cells in all investigated specimens, both
TCR-g chain genes could be ampli¢ed and sequenced success-
fully. Morphologically, there was no di¡erence between CD30þ
cells belonging to the predominant clone and their polyclonal
counterparts.
A remarkable additional observation was made in patient III,
where three samples were investigated by single cell analysis. In
biopsy IIIa, two di¡erent clonal Tcell populations were identi¢ed
(lengths of PCR products in clone 1: 241 bp, 250 bp and in clone
2: 251 bp). Clone 1 (241 bp, 250 bp) persisted during disease pro-
gression. Four of 22 CD30þ cells (18.2%) (Table I) in biopsy IIIa
showed a biallelic TCR-g chain gene rearrangement (clone 1:
241 bp, 250 bp); in subsequent samples (IIIb, IIIc), clone 1 had ex-
panded, accounting for 70^80% of all CD30þ cells in biopsy
IIIb and blood sample IIIc. Clone 2 (251 bp;Table II) was found
in ¢ve of 18 CD30þ cells taken from biopsy IIIa, showing only
one rearranged TCR-g chain gene. This clone was no longer de-
tectable in subsequent samples (IIIb, IIIc). Most CD30þ cells in
sample IIIa were of a polyclonal nature (59.1%) (Table I). In
biopsy IIIb and blood sample IIIc, the majority but not all (simi-
lar to patient I, II, and IV) of CD30þ T cells belonged to the
clonal population (74% and 78.6%, respectively). In order to con-
¢rm these results, FFA^TCR-g was performed from bulk DNA
of samples IIIa, IIIb, and IIIc. Two clonal PCR products of iden-
tical sequence lengths were demonstrated as previously detected
in single cell PCR (clone 1: 241 bp, 250 bp) (Fig 2D,E,
Table II). The second, transient, clone 2 (251 bp) most likely cor-
responds to a dominant PCR product in FFA^TCR-g (length
251 bp) in one biopsy prior to treatment (Fig 2A) and in speci-
men IIIa (Fig 2B) under vaccination therapy.
Finally, an analysis of skin samples by CGH detected the fol-
lowing chromosomal imbalances: trisomy 7 in patients I and II,
deletion of 7q and trisomy 14 in patient III and no aberration at
all in patient IV (Table I).
DISCUSSION
The CD30 antigen, a member of the tumor necrosis factor recep-
tor superfamily, has been shown to be involved in the process of
lymphoid development and di¡erentiation (Falini et al, 1995;
Gruss et al, 1996; Horie andWatanabe, 1998). Apart from its phy-
siologic function, CD30 expression may play a pivotal role in
tumorigenesis and tumor survival, as CD30 expression represents
an important diagnostic and prognostic marker in patients with
Table I. Results of micromanipulation and single cell PCR for TCR-g chain gene rearrangement in CD30þ large
pCTCL and CGH




Clonal/total sequences Polyclonal/total sequences
I Dermis Trisomy 7 Medium-sized 50 27/33 (81.8%) 6/33 (18.2%)
subcutaneous to large
fat
II Dermis Trisomy 7 Medium-sized 45 22/27 (81.5%) 5/27 (18.5%)
to large
IIIa Dermis No material Medium-sized 36 4/22 (18.2%) 13/22 (59.1%)
(5/22a) (22.7%)
IIIb Dermis, Partial deletion 7q large 54 17/23 (74%) 6/23 (26%)
subcutaneous trisomy 14
fat
IIIc Blood No material large 27 11/14 (78.6%) 3/14 (21.4%)
IV Dermis No aberration large 45 13/18 (72.2%) 5/18 (27.8%)
aIn skin biopsy IIIa identical rearrangements were found in ¢ve of 22 cells that do not belong to the tumor cell population
Table II. Clonal TCR-g rearrangements of the patients, detected by single cell PCR
Patient Allele V-gene V-segment N-sequence J-segment Length of TCR
I 1 V9 TACTACTGTGCCTTGGTGG AGAAACTTGACAGAGAAAC GAATTATTATAAGAAA 257
2 V10 TACTACTGTGCTGCGTGGG C TATTATAAGAAA 240
II 1 V4 TATTACTGTGCCACCTGGGATGGG GGCGG ATAAGAAA 249
2 V5 TATTACTGTGCCACCTGGGACAGG CCCAGCGG GAAA 248
IIIa,b,c 1 V9 TATTACTGTGCCACCTGGGA GACC TATTATAAGAAA 241
2 V10 TACTACTGTGCTGCGTGGGA AGGCCTATGTTGA TATAAAAA 250
IIIa 1 V8 TACTACTGTGCCTTGTGGGAG CCC GAATTATTATAAGAAA 251
IV 1 V10 TACTACTGTGCTGCGTGGGAT CC GAAA 235
2 V4 TACTACTGTGCCTTGTGGGATGGG TTGGG ATTATAAGAAA 252
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cutaneous lymphoma. In order to de¢ne the extent of overlap
between CD30þ large atypical cells and the malignant T cell
clone, we studied TCR-g gene sequences in single CD30þ cells
by micromanipulation and single cell PCR. Using the same ap-
proach, it has previously been demonstrated that CD30þ Reed^
Sternberg and Hodgkin cells in Hodgkin’s disease represent the
malignant cells, 90% of which are of B cell origin and 10% of
T cell origin (Kˇppers et al, 1994; Maeuschen et al, 2000).
We detected a population of T cells with clonal TCR-g gene
rearrangements in all four cases studied. All of these tumor-re-
lated cells showed a biallelic TCR-g rearrangement (Tables I
and II). Unexpectedly, we also found polyclonal T cells besides
the expected clonal population with relatively high frequency.
Previously, we have shown that T cells expressing one expanded
Vb family comprise both reactive cells and the tumor cell popu-
lation in mycosis fungoides (Gellrich et al, 2000).The role of these
bystanding T cells present within the tumor cell population
of both disease entities is currently unknown. Possibly, they
represent cytotoxic T cells.
Several studies show that cytotoxic T cells exist in cutaneous T
cell lymphoma expressing various kinds of inhibitory receptors
involved in anti-tumor responses. In this study all patients
showed a loss of CD3 within the CD30þ cell in¢ltrate. The
absence of this cell surface receptor could represent a tumor es-
cape mechanism as described by Bagot et al (2000). In the earlier
stage of disease in patient III (sample IIIa) we observed expression
of CD3 and CD4 on CD30þ cells and a relatively high number
of polyclonal T cells possibly induced by mimotope vaccination.
Paralleling clinical tumor progression a loss of CD3 and CD4
was noted (samples IIIb and IIIc), concomitant with increased
numbers of clonal cells. Thus, continued expression of CD3 and
CD4 might be relevant for an intact anti-tumor response.
Figure 2. FFA-TCR-c of Patient III. (A) Lesional skin prior to treatment:TCR-g1. (B) Lesional skin under vaccination therapy:TCR-g1. (C) Peripheral
blood lymphocytes, leukemic stage: TCR-g1. (D) Lesional skin under vaccination therapy: TCR-g2. (E) Peripheral blood lymphocytes, leukemic stage:
TCR-g2. Abscissa: sequence length in bp.Vertical axis: £uorescent intensity.
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Our ¢nding of a second expanded clonal T cell population in
sample IIIa (revealed by the same length of PCR products
(251 bp) in single cell analysis and in FFA^TCR-g) suggests the
existence of a reactive cytotoxic anti-tumor cell line (Linnemann
et al, 2000, 2001). In the peripheral blood of patient III an in-
creased number of mimotope-activated cytotoxic T cells could
be found by speci¢c interferon-g production of these cells (un-
published data).
As noted by Kadin (Mori et al, 1999), signaling pathways seem
to be important in the tumor biology of CD30þ cutaneousTcell
lymphoma. Of these, the CD30/CD30 ligand interaction may be
involved in spontaneous self-regression of tumor lesions probably
due to tumor cell apoptosis. Nevertheless, recent observations in-
dicate that aberrant cell activation by CD30 may cause the oppo-
site e¡ect: in anaplastic large cell lymphoma (ALCL) cell lines
transformed from progressed lymphomatoid papulosis lesions,
CD30/CD30 ligand signaling leads to cell proliferation instead
of cell death. Therefore, defective CD30/CD30 ligand interaction
in CD30þ tumor cells could promote tumor progression by re-
sistance to CD30-mediated growth inhibition (Mori et al, 1999;
Levi et al, 2000). Furthermore, the interaction between transform-
ing growth factor b and its receptor is compromised by muta-
tions in the transforming growth factor b receptor gene (Knaus
et al, 1996; Schiemann et al, 1999). Interestingly, tumor cells in cu-
taneous T cell lymphoma were shown to produce high amounts
of transforming growth factor b leading to the inhibition of
speci¢c anti-tumor responses (Bagot et al, 2001) and a lack of Fas
expression (Mori et al, 1999).
In contrast to the favorable clinical course generally noted in
CD30þ pCTCL two of the investigated patients (patients I and
III) underwent a highly aggressive clinical course, both dying
within 3 y. Mechanisms such as chromosomal imbalances (Bey-
lot-Barry et al, 1998; Zoi Toli et al, 2000) are considered important
in tumor progression. In line with this notion, we detected a tris-
omy 7 in patients I and II as well as a partial deletion of 7q and a
trisomy 14 in patient III by CGH analysis; however, whether
these aberrations are present in the clonal, the polyclonal, or both
populations remains an open question at present.
In conclusion, our results demonstrate that CD30þ large aty-
pical T lymphocytes in CD30þ large pCTCL indeed include
clonally rearranged cells, and thus the tumor clone, but do not
represent a uniform cell population, but rather a mixture of clo-
nal and polyclonal T lymphocytes. With regard to the role of
polyclonal CD30þ Tcells within the tumor lesions, we speculate
that strongT cell activating factors, i.e.,T helper 2 type cytokines
are active within the lesion, inducing common morphologic, and
likely functional, features both in malignant in bystander T cells
(Li et al, 1997). As activated Tcells are probably more vulnerable to
the genetic alterations detected in our patients, such local stimuli
may be directly involved in the initial phases of lymphoma
genesis.
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